CLINICAL, PARACLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF HOSPITALIZED PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AT THUAN AN AN REGIONAL MEDICAL CENTER
Main Article Content
Abstract
Objective: This study aimed to describe the clinical and paraclinical characteristics, treatment outcomes of hospitalized patients with chronic obstructive pulmonary disease (COPD), and to analyze the association between blood eosinophil count (BEC) and treatment outcomes.
Methods: A cross-sectional descriptive study was conducted on 79 patients.
Results: The majority were elderly males (≥60 years: 65.8%) with a history of smoking (97.5%). Most patients presented with typical symptoms and were classified into severe groups (GOLD C and D: 94.9%). The proportion of patients with BEC ≥300 cells/µL was 60.8%. Most patients received combination antibiotic therapy with cephalosporins. The mean length of hospital stay was 9 days, and the readmission rate was 63.3%. Patients with BEC ≥300 cells/µL had a higher risk of readmission but a shorter length of hospital stay (p < 0.001).
Conclusion: Hospitalized COPD patients were predominantly elderly males with severe clinical characteristics. Elevated BEC was common and was associated with treatment outcomes, particularly an increased risk of readmission.
Keywords
Chronic obstructive pulmonary disease, eosinophils, COPD exacerbation
Article Details
References
2. Organization WH. Chronic obstructive pulmonary disease (COPD): World Health Organization; 2023. Available from:https://www.who.int/news-room/fact-sheets/ detail/chronic-obstructive-pulmonary-disease-(copd)
3. Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. Journal of Global Health. 2022;12:04074. doi: 10.7189/jogh.12.04074.
4. Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. The Lancet Respiratory Medicine. 2018;6(2):117-126. doi: 10.1016/S2213-2600(18)30006-7.
5. Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015 Jun;3(6):435-42. doi: 10.1016/s2213-2600(15)00106-x. PubMed PMID: 25878028; eng.
6. Chen F, Yang M, Wang H, et al. High blood eosinophils predict the risk of COPD exacerbation: A systematic review and meta-analysis. PLoS One. 2024;19(10):e0302318. doi: 10.1371/journal.pone.0302318.
7. Zhang Y, Chen X, Li J, et al. Prognostic value of blood eosinophil level in acute exacerbation of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease. 2023;18:2315-2324. doi: 10.2147/copd.S417123.